Introduction
============

The digital diabetes ecosystem is booming \[[@ref1],[@ref2]\], with more than 1500 mobile apps supporting diabetes management \[[@ref3]\], yet very few diabetes apps have been studied. For the few that have, they significantly reduce glycated hemoglobin A~1c~ (HbA~1c~) by an average 0.49% \[[@ref4]\].

The HbA~1c~ measurement is the amount of hemoglobin in the blood with glucose attached to it. People are diagnosed with diabetes when their HbA~1c~ level is 6.5% or greater. An HbA~1c~ of 7.0% or greater puts people with diabetes at risk of developing macrovascular and microvascular complications, whereas a HbA~1c~ less than 7.0% or reducing HbA~1c~ by 1.0% prevents complications \[[@ref5],[@ref6]\]. Diabetes self-care (eg, eating fewer carbohydrate grams, being more active, taking medications) improves HbA~1c~ levels.

Diabetes apps offer tracking of self-care and can educate and motivate people to better care for their health \[[@ref1]\]. Together, the widely used diabetes apps rate highly in terms of functionality, aesthetics, and engagement \[[@ref7]\]. Devices, sensors, wearables, and watches that passively collect data may bolster engagement. Passive data collection makes a more useful and less burdensome diabetes app \[[@ref1],[@ref8]\]. Very few apps, however, offer manual and passive data collection from a mobile phone and a smartwatch, and no study to our knowledge has explored the health benefit of this type of digital solution.

The One Drop \| Mobile app offers manual data entry, but also passive data collection via Apple's HealthKit, Apple Watch, and the Bluetooth-enabled One Drop \| Chrome glucose meter. We hypothesized that there would be a pre-post HbA~1c~ change among people with diabetes using the One Drop \| Mobile app on an iPhone and Apple Watch. We also hypothesized self-care tracking with the app would be associated with HbA~1c~ change.

Methods
=======

One Drop \| Mobile: A Mobile Phone and Smartwatch App
-----------------------------------------------------

The One Drop \| Mobile app is free and available on iOS, WatchOS, and Android operating systems. One Drop users manually and passively (via HealthKit for iPhone and Apple Watch, Google Fit for Android mobile phones, and the Bluetooth-enabled One Drop \| Chrome blood glucose meter) store and track blood glucose readings, medication doses, physical activity, and carbohydrates consumed. A built-in food library expedites carbohydrate tracking. A medication scheduler reminds users when a dose is due, and tracks doses upon confirmation. Statistics of tracked data are viewable on iPhone, Android, and Apple Watch.

Watch app users can enter data directly from their Watch, and view statistics of their data and monitor goal progress on the Watch face. They can get push notifications on their Watch, including medication reminders and motivational messages prompting and reinforcing self-care.

On the mobile phone app, users can view in-depth statistics of their data and track HbA~1c~ test results and body weight. An in-app "Newsfeed" delivers health tips, articles, infographics, and more. A "Community" section facilitates learning from, supporting, and receiving support from other users. The iPhone app has a "Notifications" inbox with data-driven insights, achievements, reminders, and support accumulated from other users.

Procedures
----------

On June 6, 2017, we identified people with type 1 (T1D) or type 2 diabetes (T2D) using the One Drop \| Mobile app on an iPhone and Apple Watch who had manually entered at least two HbA~1c~ values in the app with HbA~1c~ test dates 60 to 365 days apart. We did not recruit participants. Instead, we analyzed data collected from real users who elected to use the One Drop \| Mobile app on their mobile phone and smartwatch devices.

Users enter and store self-care and health data in the One Drop \| Mobile app. All data exist in a secure server in the cloud. We characterized users with app-entered demographics (eg, gender, diabetes type). We tested their HbA~1c~ change (ie, self-reported HbA~1c~ collected in the app). We also tested if tracking self-care with the app (ie, the number of times food, activity, blood glucose, and medications were stored in the app between HbA~1c~ measurements) was associated with HbA~1c~ change.

All users agree to an end-user license agreement (EULA). In this agreement, it states that, as a user, you "grant One Drop a perpetual, transferrable, sublicensable, worldwide, nonexclusive, royalty-free license to reproduce, distribute, use, modify, remove, publish, transmit, publicly perform, publicly display, or create derivative works of Your User Content for any purpose without compensation to you, including for the purpose of promoting One Drop and the App, including after your account is cancelled or otherwise terminated." It also states that, "One Drop\...may track and report your activity inside of the App, including for analytics purposes." The full EULA is available in the app and online.

Measures
--------

### User Characteristics

Gender, diabetes type, and year of diagnosis are self-reported in the app. The difference between year of diagnosis and year of One Drop account creation determined years of diagnosed diabetes. Passively collected time zone data determined user location. User location was dichotomized as United States versus non-United States in analyses because few users outside the United States had entered two HbA~1c~ measurements required for inclusion.

### Insulin Status

We reviewed medication names tracked and scheduled in the app to determine if a user was taking insulin or not.

### Self-Care

We summed self-care data tracked between two HbA~1c~ entries (60-365 days apart), generating counts of blood glucose, food (carbohydrates), medications, activity, and the overall number of self-care entries tracked in the app during that time.

### Glycemic Control

Test results and test dates of HbA~1c~ were self-reported in the app. Self-reported recall of a HbA~1c~ test is highly sensitive (99%) to medical records and claims data documenting an actual HbA~1c~ test \[[@ref9]\]. A self-reported HbA~1c~ result is sensitive (79%) to a lab HbA~1c~ test result \[[@ref10]\]. Further, we used mean blood glucose measured before the second HbA~1c~ test date to exclude invalid HbA~1c~ measurements and, subsequently, validate self-reported HbA~1c~ at that time point (see Analyses section).

We used HbA~1c~ test dates to calculate the number of days between HbA~1c~ entries. We divided 365 days by 12 months to get 30.42 (days per) month. We divided the number of days between HbA~1c~ entries by 30.42 (days per) month to get the number of months between HbA~1c~ measurements.

Study Oversight
---------------

One Drop, Informed Data Systems Inc (IDS) received an exemption for institutional review board approval and a waiver of informed consent from Solutions IRB, an independent ethics review company (Little Rock, AR and Yarnell, AZ) to study all de-identified data owned by One Drop IDS. All One Drop \| Mobile app users must actively agree to a EULA detailing data ownership and use.

Analyses
--------

All analyses were performed using SPSS version 23 (IBM Corp). Summary statistics characterized the sample. Mann-Whitney *U* tests were used for diabetes type differences with continuous variables, and chi-square tests for differences with dichotomous variables. One user with T1D selected "other" for gender. Because "other" gender was infrequently selected, we removed the "other" gender subgroup prior to testing diabetes type differences on gender.

To exclude invalid self-reported HbA~1c~ data, we used the formula HbA~1c~=(90-day mean blood glucose + 77.3)/35.6 \[[@ref11]\] to compare self-reported HbA~1c~ to 90-day mean blood glucose, and excluded users with a greater or less than 2.0% difference (n=44 were excluded). Spearman rho correlations verified the relationship between self-reported HbA~1c~ and mean blood glucose consistent with prior research \[[@ref12]\].

Two variables had missing data: gender (37/256, 14.4%) and duration of diagnosed diabetes (47/256, 18.3%). Multiple imputation corrected for missing data on these variables \[[@ref13]\]. We used predictive mean matching \[[@ref14],[@ref15]\] to impute 100 datasets.

Three mixed-effects repeated measures models tested mean HbA~1c~ differences. The first unadjusted model tested the effects of time, diabetes type, and the interaction of time by diabetes type. The second model tested these effects adjusted for a priori covariates: gender, location, years of diagnosed diabetes, and months between HbA~1c~ measurements. We restricted the third model to users with T2D and tested the time effect only adjusted for a priori covariates and insulin status.

Finally, four multiple regression models tested relationships between self-care tracking with the app and HbA~1c~ change. The first unadjusted model assessed the relationships between the amount of tracking by self-care type and HbA~1c~ change. The second model introduced diabetes type. The third model added a priori covariates. The fourth model included users with T2D only, a priori covariates, and insulin status.

Results
=======

Users (N=256) had T1D (n=65) or T2D (n=191), and were 22.7% (58/219) female, diagnosed with diabetes for a mean 8.34 (SD 8.79) years, and tracked a mean 2176.35 (SD 3430.23) self-care activities in the app between HbA~1c~ entries. Across each of four self-care types, the Shapiro-Wilk test statistic ranged from 0.22 to 0.86 (all *P*\<.001), signifying a non-normal distribution. We dichotomized each self-care variable to tracked versus not tracked to satisfy assumptions of statistical tests.

[Table 1](#table1){ref-type="table"} presents median and interquartile ranges, n (%), or mean and standard deviation with *P* values for diabetes type differences on observed variables before multiple imputation. Compared to users with T2D, users with T1D had diabetes for more years and entered more self-care data in the app between HbA~1c~ measurements, particularly blood glucose readings. Self-reported HbA~1c~ and 90-day mean blood glucose were strongly correlated (ρ=.75, *P*\<.001), even when stratified by diabetes type (T1D: ρ=.84, *P*\<.001; T2D: ρ=.72, *P*\<.001). This is consistent with previous cohort studies reporting correlations varying from .71 to .86 \[[@ref12]\].

In unadjusted and adjusted models, there was a significant 1.36% (14.9 mmol/mol) HbA~1c~ reduction (unadjusted and adjusted *F*=62.60, *P*\<.001) during a median 4.06 (IQR 2.82) months (unadjusted: 8.26% \[66.8 mmol/mol\] to 6.90% \[51.9 mmol/mol\]; adjusted 8.72% \[71.8 mmol/mol\] to 7.36% \[56.9 mmol/mol\]). In the adjusted model, users with T1D had an average 0.41% (*F*=4.38, *P=*.04) higher HbA~1c~ than users with T2D, but there was no time by diabetes type interaction. After adjusting for a priori covariates and insulin status, users with T2D had a 1.27% (13.9 mmol/mol) HbA~1c~ reduction (*F*=364.50, *P*\<.001; 8.16% \[65.7 mmol/mol\] to 6.89% \[51.8 mmol/mol\]).

Finally, using the app to track carbohydrates was associated with greater HbA~1c~ improvement even after adjusting for covariates and insulin status for users with T2D (all *P*\<.01).

###### 

Sample characteristics with tests of difference by diabetes type.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  User characteristics                       Total (N=256)                                  Type 1 diabetes (n=65)   Type 2 diabetes (n=191)   *P*^a^          
  ------------------------------------------ ---------------------------------------------- ------------------------ ------------------------- --------------- ------
  **Gender, n (%)**                          \                                              \                        \                         \               

  \                                          Male                                           161 (62.9)               40 (61.5)                 121 (63.4)      .91

  \                                          Female                                         58 (22.7)                14 (21.5)                 44 (23.0)       \

  **Location, n (%)**                        \                                              \                        \                         \               

  \                                          United States                                  217 (84.8)               54 (83.1)                 163 (85.4)      .66

  \                                          Europe                                         27 (10.5)                9 (13.8)                  18 (9.4)        \

  \                                          Asia                                           8 (3.1)                  2 (3.1)                   6 (3.1)         \

  \                                          Pacific                                        2 (0.8)                  0                         2 (1.0)         \

  \                                          Africa                                         2 (0.8)                  0                         2 (1.0)         \

  **Diabetes duration (years), mean (SD)**   8.3 (8.8)                                      13.3 (11.6)              7.1 (7.7)                 \<.001          

  Insulin status (yes), n (%)                136 (53.1)                                     65 (100)                 71 (37.2)                 \<.001          

  **Self-care, n (%)**                       \                                              \                        \                         \               

  \                                          App self-care entries                          1439.5 (1809)            2055.0 (4264)             1318.0 (1463)   .002

  \                                          Food entries                                   17.0 (166)               15.0 (150)                18.0 (178)      .67

  \                                          Activity entries                               628.5 (1049)             470.0 (1170)              664.0 (966)     .31

  \                                          Blood glucose entries                          115.0 (243)              193.0 (567)               94.0 (210)      .02

  \                                          Medication entries                             221.0 (452)              279.0 (3657)              207.0 (367)     .06

  **Glycemic control**                       \                                              \                        \                         \               

  \                                          Months between HbA~1c~ entries, median (IQR)   4.06 (2.82)              5.16 (4.29)               3.88 (2.66)     .003

  \                                          First HbA~1c~ (%), mean (SD)                   8.23 (2.27)              8.31 (2.47)               8.20 (2.20)     .87

  \                                          Second HbA~1c~ (%), mean (SD)                  6.80 (0.99)              7.09 (1.15)               6.70 (1.39)     .01
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ From chi-square or Mann-Whitney *U* tests.

Discussion
==========

We assessed the HbA~1c~ change of 256 people with diabetes using the One Drop \| Mobile app on an iPhone and Apple Watch for up to one year. HbA~1c~ decreased by 1.36% (14.9 mmol/mol) in a median of approximately 4 months. Using the app to track carbohydrates was independently associated with HbA~1c~ improvement.

To our knowledge, this study is the first to evaluate the HbA~1c~ benefit of a tethered diabetes mobile phone and smartwatch app. One study asked people with T1D to use a phone and smartwatch app and give qualitative feedback \[[@ref16]\]. Users appreciated entering and viewing data from their watch, the watch's connectivity to their phone, and viewing reminders on their watch. One Drop \| Mobile on Apple Watch delivers all three benefits and, based on our findings, may improve glycemic control.

There are study limitations. This is not a randomized controlled trial, preventing causal conclusions. The sample was self-selected, limiting generalizability. HbA~1c~ measurements were self-reported rather than assessed with a laboratory assay. Passively collected data are less prone to social desirability biases, but have their own reliability and validity issues \[[@ref17]\]. The One Drop \| Mobile app has features we did not evaluate or adjust for in our analyses. Finally, we do not know users' age or socioeconomic status (eg, income, education, insurance status), preventing generalizability to all ages and socioeconomic groups.

Despite these limitations, people of all ages \[[@ref18]\], race/ethnicities, and socioeconomic backgrounds \[[@ref19]\] increasingly want to use smart devices to assist in the management of diabetes \[[@ref20]\]. Research needs to critically evaluate diabetes apps, trackers, and smartwatches, especially as new devices enter the marketplace. Findings must be disseminated directly to consumers and to physicians who can assess these tools and make recommendations accordingly.
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